BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025
None
The most recent news, dated October 13, 2025, announces that BriaCell will present positive clinical biomarker data from its ongoing pivotal Phase 3 study of Bria-IMT™ in advanced metastatic breast cancer (MBC) at the upcoming European Society for Medical Oncology (ESMO) Congress.
The key findings from a blinded analysis of 68 patients are: * The trend of biomarkers identified in the previous Phase 2 study is being replicated in the current Phase 3 trial. * A specific immune response, delayed-type hypersensitivity (DTH), was found to be significantly associated with longer progression-free survival (PFS) with a p-value of 0.0002. * The drug candidate, Bria-IMT™, continues to be well-tolerated, with no new safety concerns identified.
An earlier press release on October 3, 2025, announced a separate presentation of preclinical data for another product candidate, Bria-OTS+™, at the SITC 2025 Annual Meeting.
The news is positive but its material impact is limited at this stage.
Positive Aspects: * Thesis Confirmation: The data supports the company's central hypothesis that Bria-IMT™ can generate an immune response (DTH) that correlates with a positive clinical outcome (longer PFS). A highly significant p-value (0.0002) strengthens this correlation. * De-risking: Seeing similar biomarker trends from Phase 2 continue into Phase 3 provides an incremental de-risking of the ongoing trial. It suggests the drug's mechanism of action is consistent. * Clean Safety Profile: The continued safety and tolerability are crucial for any new therapy, especially for heavily pre-treated patients (median of 6 prior treatments).
Critical Limitations (Risks): * Blinded Data: This is the most significant caveat. The analysis was conducted without knowing which patients received Bria-IMT™ and which received the physician's choice of therapy. It's possible that patients with a healthier immune system are more likely to exhibit a DTH response and have better outcomes, regardless of the treatment received. The data shows a correlation, but it does not yet prove causation by Bria-IMT™. * Biomarker, Not Primary Endpoint: The positive correlation is with Progression-Free Survival (PFS), which is a secondary endpoint. The study's primary endpoint, and the one most critical for FDA approval, is Overall Survival (OS). While related, improved PFS does not always translate to improved OS. * Interim & Incomplete: The data is from a small subset (68 patients) of the overall trial. The key catalyst remains the pre-planned interim analysis for OS, which requires 144 patient events (deaths) to be triggered.
In summary, the news is an encouraging update that aligns with prior expectations from Phase 2. It keeps the investment thesis alive and provides a positive talking point for the upcoming conference. However, for a risk-averse investor, this is not the definitive data needed to change the fundamental risk profile of the company. It is a step in the right direction, but the major binary risk event—the unblinded OS data—is still in the future.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. Its flagship project is Bria-IMT™, a whole-cell immunotherapy designed to treat advanced metastatic breast cancer. Bria-IMT™ is currently in a pivotal international Phase 3 clinical trial and has received Fast Track designation from the U.S. FDA.